These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349 [TBL] [Abstract][Full Text] [Related]
6. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo. Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305 [TBL] [Abstract][Full Text] [Related]
8. B7-H3-targeted CAR-T cell therapy for solid tumors. Li G; Wang H; Wu H; Chen J Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615 [TBL] [Abstract][Full Text] [Related]
9. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714 [TBL] [Abstract][Full Text] [Related]
10. The role of B7-H3 in tumors and its potential in clinical application. Feng R; Chen Y; Liu Y; Zhou Q; Zhang W Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689 [TBL] [Abstract][Full Text] [Related]
11. B7-H3-mediated tumor immunology: Friend or foe? Wang L; Kang FB; Shan BE Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874 [TBL] [Abstract][Full Text] [Related]
12. B7-H3 in Brain Malignancies: Immunology and Immunotherapy. Guo X; Chang M; Wang Y; Xing B; Ma W Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196 [TBL] [Abstract][Full Text] [Related]
13. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149 [TBL] [Abstract][Full Text] [Related]
14. B7x in cancer immunity and immunotherapy. Mortezaee K Int Immunopharmacol; 2023 May; 118():110133. PubMed ID: 37028278 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773 [TBL] [Abstract][Full Text] [Related]
16. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560 [TBL] [Abstract][Full Text] [Related]
17. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824 [TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities. Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649 [TBL] [Abstract][Full Text] [Related]
19. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467 [No Abstract] [Full Text] [Related]
20. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]